口服降糖药物联合司美格鲁肽治疗肥胖2型糖尿病1例被引量：2

Oral hypoglycemic drugs combined with semaglutide in the treatment of obese type 2 diabetes mellitus:a case report

导出

摘要回顾性分析1例在新疆医科大学第一附属医院内分泌科服用口服降糖药治疗肥胖的2型糖尿病(T2DM)患者,转换为司美格鲁肽联合二甲双胍及钠-葡萄糖共转运蛋白2抑制剂的降糖及减重效果,并进行文献复习。患者38岁男性,因“发现血糖高5年”入院,既往明确诊断为T2DM,口服降糖药物治疗,血糖控制不达标,改为司美格鲁肽联合口服降糖药物,治疗3个月后,血糖控制良好,体重较前下降17 kg,糖化血红蛋白达标。司美格鲁肽可通过减少食欲和饥饿感、减少能量摄入、增加饱腹感、改变食物偏好、延缓胃排空等机制起到减重的作用,并有助于改善脂肪肝,可用于超重或肥胖的T2DM合并脂肪肝患者。

作者魏伊函李蕾王飞阿勒滕齐齐格蒋升 Wei Yihan;Li Lei;Wang Fei;Aletengqiqige;Jiang Sheng(Department of Endocrinology,First Affiliated Hospital of Xinjiang Medical University,Urumqi 830011,China)

机构地区新疆医科大学第一附属医院内分泌科

出处《中华糖尿病杂志》 CAS CSCD 北大核心 2022年第S01期150-152,共3页 CHINESE JOURNAL OF DIABETES MELLITUS

关键词糖尿病 2型肥胖症重度脂肪肝胰高糖素样肽-1受体激动剂

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献3

1杨帆,李钶,蒋晓岚,李健,王翔,曾庆华,余婷婷.利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响研究[J].重庆医学,2016,45(25):3493-3495. 被引量：47
2邢国庆,于苏国.司美格鲁肽治疗肥胖的研究进展[J].国际医药卫生导报,2022,28(7):898-901. 被引量：7
3韩美芬,赵彬,陈伟,刘晓军,杨长青.司美格鲁肽在治疗肥胖症中的作用机制及临床应用进展[J].中国新药杂志,2022,31(9):859-862. 被引量：21

二级参考文献26

1Vernon G,Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults [J].Alim Pharmacol Thers,2011,30(3) :274-285.
2Praveenraj P, Gomes RM, Kumar S,et al. Prevalence and predictors of non -alcoholic fatty liver disease in morbidly obese south Indian patients undergoing bariatric surgery [J]. Obes Surg,2015,25(11) :2078-2087.
3Conlon BA, Beasley JM, Aebersold K, et al. Nutritional management of insulin resistance in nonalcoholic fatty liv- er disease (NAFLD) [J]. Nutrients, 2013,5 (10) : 4093- 4114.
4Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians[J]. J Family ivied Prim Care,2015,4(1) :45-52.
5Lonardo A,Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome [J]. Dig Liver Dis,2015,47(3) :181-190.
6Kumar M, Rastogi A, Singh T, et al. Controlled attenua- tion parameter for non-invasive assessment of hepatic steatosis : does etiology affect performance[J]. J Gastroen- terol Hepatol, 2013,28(7) : 1194-1201.
7Douali N, Abdennour M, Sasso M, et al. Noninvasive diag- nosis of nonalcoholic steatohepatitis disease based on clin- ical decision support system[J]. Stud Health Technol In- form, 2013,192 : 1178.
8Myers RP,Pomier-Layrargues G,Kirsch R,et al. Feasibil- ity and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients[J]. H epatology, 2012,55 (1) : 199-208.
9Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome [J]. Dig Liver Dis,2015,47(3):181-190.
10Gao HT, Xu LS, Li DF, et al. Effects of glucagon-like peptide-1 on liver oxidative stress,TNF-a and TGF-β1 in rats with non-alcoholicfatty liver disease [J]. J South Med Univ,2013,33(11) : 1661-1664.